Cargando…
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
BACKGROUND: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. METHODS: Patients with Stage II-IV locally advanced or metastatic...
Autores principales: | Laquente, Berta, Lopez-Martin, Jose, Richards, Donald, Illerhaus, Gerald, Chang, David Z., Kim, George, Stella, Philip, Richel, Dirk, Szcylik, Cezary, Cascinu, Stefano, Frassineti, G. L., Ciuleanu, Tudor, Hurt, Karla, Hynes, Scott, Lin, Ji, Lin, Aimee Bence, Von Hoff, Daniel, Calvo, Emiliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312529/ https://www.ncbi.nlm.nih.gov/pubmed/28202004 http://dx.doi.org/10.1186/s12885-017-3131-x |
Ejemplares similares
-
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
por: Patnaik, Amita, et al.
Publicado: (2018) -
Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016) -
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
por: Gelbert, Lawrence M., et al.
Publicado: (2014) -
Developmental and communicative interrelations of Ly123 and Ly1 cell sets
Publicado: (1980) -
A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)